ABSTRACT
During the early wave of the COVID-19 pandemic, the Scientific Registry of Transplant Recipients (SRTR) designated a "black out" period between March 12, 2020, and June 12, 2020, for transplant outcomes reporting. We discuss the implications and potential bias it has introduced as it may selectively favor the outcomes for certain regions and harm other regions due to varied effects of different waves of COVID-19 infections across the United States.
Subject(s)
COVID-19 , Organ Transplantation , Tissue and Organ Procurement , Transplants , COVID-19/epidemiology , Humans , Pandemics , Registries , Transplant Recipients , United States/epidemiologySubject(s)
COVID-19 , SARS-CoV-2 , Antibodies, Viral , Biomarkers , Humans , Immunity, Humoral , Trust , VaccinationABSTRACT
Transplant centers seeking to increase coronavirus disease 2019 (COVID-19) vaccine coverage may consider requiring vaccination for healthcare workers or for candidates. The authors summarize current data to inform an ethical analysis of the harms, benefits, and individual and societal impact of mandatory vaccination, concluding that vaccine requirements for healthcare workers and transplant candidates are ethically justified by beneficence, net utility, and fiduciary duty to patients and public health. Implementation strategies should mitigate concerns about respect for autonomy and transparency for both groups. We clarify how the same arguments might be applied to related questions of caregiver vaccination, allocation of other healthcare resources, and mandates for non-COVID-19 vaccines. Finally, we call for effort to achieve global equity in vaccination as soon as possible.
Subject(s)
COVID-19 Vaccines , Vaccination , COVID-19 , Ethical Review , Health Personnel , Humans , PatientsSubject(s)
COVID-19 , Organ Transplantation , COVID-19 Vaccines , Humans , SARS-CoV-2 , Transplant Recipients , VaccinationSubject(s)
COVID-19 , Organ Transplantation , Humans , Organ Transplantation/adverse effects , Pandemics , SARS-CoV-2 , Transplant RecipientsABSTRACT
Solid organ transplant (SOT) recipients are at increased risk of influenza disease and associated complications. The mainstay of prevention is the annual standard-dose influenza vaccine, as studies showed decreased influenza-related morbidity and mortality in vaccinated SOT recipients compared to those unvaccinated. Nonetheless, the immune response in this high-risk population is suboptimal compared to healthy individuals. Over the past two decades, several vaccination strategies have been investigated to overcome this inadequate immune response in SOT recipients. Howbeit, the best vaccination strategy and optimal timing of influenza vaccination remain unclear. This review will provide a detailed summary of studies of various influenza vaccination strategies in adult SOT recipients, discussing immunogenicity results, and addressing their limitations and knowledge gaps.
Subject(s)
Influenza Vaccines , Influenza, Human , Organ Transplantation , Adult , Humans , Influenza, Human/prevention & control , Organ Transplantation/adverse effects , Transplant Recipients , VaccinationABSTRACT
The novel coronavirus disease 2019 (COVID-19) is impacting transplant programs around the world, and, as the center of the pandemic shifts to the United States, we have to prepare to make decisions about which patients to transplant during times of constrained resources. In this paper, we discuss how to transition from the traditional justice versus utility consideration in organ allocation to a more nuanced allocation scheme based on ethical values that drive decisions in times of absolute scarcity. We recognize that many decisions are made based on the practical limitations that transplant programs face, especially at the extremes. As programs make the transition from a standard approach to a resource-constrained approach to transplantation, we utilize a framework for ethical decisions in settings of absolutely scarce resources to help guide programs in deciding which patients to transplant, which donors to accept, how to minimize risk, and how to ensure the best utilization of transplant team members.